BR0116017A - Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo - Google Patents

Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo

Info

Publication number
BR0116017A
BR0116017A BR0116017-6A BR0116017A BR0116017A BR 0116017 A BR0116017 A BR 0116017A BR 0116017 A BR0116017 A BR 0116017A BR 0116017 A BR0116017 A BR 0116017A
Authority
BR
Brazil
Prior art keywords
alpha
tgf
vaccine composition
autologous
vaccine
Prior art date
Application number
BR0116017-6A
Other languages
English (en)
Inventor
Aillette Mulet Sierra
Rolando Perez Rodriguez
Gisela Maria Gonzale Marinello
Anabel Alvarez Costa
Tamara Menendez Medina
Gerardo Enrique Guillen Nieto
Belinda Sanchez Ramirez
Original Assignee
Ct De Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Immunologia Molecular filed Critical Ct De Immunologia Molecular
Publication of BR0116017A publication Critical patent/BR0116017A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Abstract

"COMPOSIçãO DE VACINA CAPAZ DE PRODUZIR UMA RESPOSTA IMUNE ESPECìFICA CONTRA O TGF-ALFA AUTóLOGO". A presente invenção está relacionada com o campo da imunologia e da medicina humana, em particular com a imunoterapia ativa específica de tumores malignos dependentes do TGFa para seu crescimento, e também com o tratamento de outras doenças que dependam do TGFa, através de uma preparação de vacina capaz de provocar uma reação de imunocastração do TGFa autólogo. Outro objeto importante desta invenção é a obtenção de uma preparação de vacina que inclua uma combinação do TGFa com outros ligandos do EGF-R, como o fator de crescimento epidérmico (EGF), capaz de inibir a proliferação de tumores cuja progressão depende destes fatores de crescimento. Desta maneira evita-se a resistência que o tumor pode gerar contra vacinas que contenha cada uma destas moléculas em separado.
BR0116017-6A 2000-12-06 2001-12-06 Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo BR0116017A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
PCT/CU2001/000011 WO2002045738A2 (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa

Publications (1)

Publication Number Publication Date
BR0116017A true BR0116017A (pt) 2004-01-13

Family

ID=34109588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116017-6A BR0116017A (pt) 2000-12-06 2001-12-06 Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo

Country Status (21)

Country Link
US (1) US20030054011A1 (pt)
EP (1) EP1339425B1 (pt)
JP (1) JP2004521091A (pt)
KR (1) KR100834383B1 (pt)
CN (2) CN1482916A (pt)
AR (1) AR031785A1 (pt)
AT (1) ATE439855T1 (pt)
AU (2) AU2152002A (pt)
BR (1) BR0116017A (pt)
CA (1) CA2430621A1 (pt)
CU (1) CU23077A1 (pt)
DE (1) DE60139633D1 (pt)
EA (1) EA006240B1 (pt)
ES (1) ES2332125T3 (pt)
MX (1) MXPA03005031A (pt)
MY (1) MY141122A (pt)
NZ (1) NZ526283A (pt)
PE (1) PE20020696A1 (pt)
UY (1) UY27060A1 (pt)
WO (1) WO2002045738A2 (pt)
ZA (1) ZA200304416B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101323845B1 (ko) 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CN113855792B (zh) * 2021-12-01 2022-03-01 上海惠盾因泰生物科技有限公司 重组hEGF-CRM197肿瘤治疗性疫苗配制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals

Also Published As

Publication number Publication date
EA006240B1 (ru) 2005-10-27
AU2002221520B2 (en) 2007-10-11
MXPA03005031A (es) 2004-09-10
UY27060A1 (es) 2002-03-22
MY141122A (en) 2010-03-15
US20030054011A1 (en) 2003-03-20
AU2152002A (en) 2002-06-18
KR100834383B1 (ko) 2008-06-09
JP2004521091A (ja) 2004-07-15
EP1339425A2 (en) 2003-09-03
EP1339425B1 (en) 2009-08-19
EA200300638A1 (ru) 2003-10-30
CN101406692A (zh) 2009-04-15
CA2430621A1 (en) 2002-06-13
DE60139633D1 (de) 2009-10-01
ES2332125T3 (es) 2010-01-27
CU23077A1 (es) 2005-08-17
WO2002045738A3 (es) 2003-02-20
KR20030061424A (ko) 2003-07-18
AR031785A1 (es) 2003-10-01
WO2002045738A2 (es) 2002-06-13
NZ526283A (en) 2004-11-26
PE20020696A1 (es) 2002-09-19
CN1482916A (zh) 2004-03-17
ATE439855T1 (de) 2009-09-15
ZA200304416B (en) 2004-07-07

Similar Documents

Publication Publication Date Title
De Simone et al. Role of TH17 cytokines in the control of colorectal cancer
Markota et al. Targeting interleukin-22 for cancer therapy
CN103103246B (zh) 活化辅助t细胞的方法以及用于该方法的组合物
Kim et al. Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability
BR0116017A (pt) Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo
Novoselova et al. Effects of low-level combined static and weak low-frequency alternating magnetic fields on cytokine production and tumor development in mice
Vander Poorten et al. Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue
Kelly et al. Endothelial growth factor present in tissue culture of CNS tumors
Sedlacek et al. Regression of spontaneous mammary tumors in dogs after injection of neuraminidase‐treated tumor cells
Kim et al. Effects of extremely low frequency electromagnetic fields on melanogenesis through p-ERK and p-SAPK/JNK pathways in human melanocytes
Gerlach et al. The dichotomous function of interleukin-9 in cancer diseases
Janowska et al. The genetic basis of dormancy and awakening in cutaneous metastatic melanoma
CN106794230A (zh) 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
Simanovich et al. Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation
Hua et al. Eucalyptal A inhibits glioma by rectifying oncogenic splicing of MYO1B mRNA via suppressing SRSF1 expression
CN101569746A (zh) 抗肿瘤复合疫苗
CU22979A1 (es) Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
Ruella et al. Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma
Schuster et al. Granulocyte-colony stimulating factor: a new player for the enteric nervous system
Sorrentino et al. CpG‐ODN increases the release of VEGF in a mouse model of lung carcinoma
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
Gaudernack et al. Combination of GM-CSF with antitumour vaccine strategies
Tian et al. TRIM59: a membrane protein expressed on bacillus Calmette-Guerin-activated macrophages that induces apoptosis of fibrosarcoma cells by direct contact
Zhang et al. A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma
Daneshmandi et al. Engineering tumor cells with tumor necrosis factor α (TNF-α) or CD40 ligand (CD40L) genes induce anti-tumor immune responses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.